Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New developments in iron chelators.

Melody J Cunningham1, David G Nathan

  • 1Harvard Medical School, Children's Hospital, Boston, MA 02115, USA. Melody.Cunningham@childrens.harvard.edu

Current Opinion in Hematology
|February 24, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correcting the record on anemia of aging: a statistical reanalysis.

Blood advances·2023
Same author

COVID-19, nuclear war, and global warming: lessons for our vulnerable world.

Lancet (London, England)·2020
Same author

The Genetic Landscape of Diamond-Blackfan Anemia.

American journal of human genetics·2019
Same author

The Genetic Landscape of Diamond-Blackfan Anemia.

American journal of human genetics·2018
Same author

The Pathophysiology of Acquired Aplastic Anemia: Current Concepts Revisited.

Hematology/oncology clinics of North America·2018
Same author

Incorporating Bereaved Parents as Faculty Facilitators and Educators in Teaching Principles of Palliative and End-of-Life Care.

The American journal of hospice & palliative care·2018
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

New iron chelators offer improved delivery and efficacy for iron overload disorders. These advancements promise better patient outcomes in thalassemia and other conditions requiring chelation therapy.

Area of Science:

  • Pharmacology
  • Hematology
  • Toxicology

Background:

  • Deferoxamine has been the sole approved iron chelator for 30 years.
  • Its short half-life and parenteral administration present significant challenges.
  • The need for improved iron chelation therapies is critical.

Purpose of the Study:

  • To review novel oral iron chelators.
  • To discuss modified deferoxamine formulations with prolonged half-lives.
  • To cover methods for monitoring iron overload.

Main Methods:

  • Review of recent preclinical and clinical trials.
  • Analysis of safety and efficacy data for new chelators.
  • Evaluation of novel administration regimens.

Related Experiment Videos

Main Results:

  • Several oral iron chelators are under investigation.
  • Variations of deferoxamine aim to extend its therapeutic half-life.
  • Ongoing trials assess the safety and efficacy of these new agents.

Conclusions:

  • Recent discoveries in chelation therapy offer significant improvements.
  • Novel approaches to iron chelation can enhance patient care.
  • Improved clinical outcomes are anticipated for patients with iron overload disorders.